Original language | English (US) |
---|---|
Pages (from-to) | 1052-1055 |
Number of pages | 4 |
Journal | Journal of Allergy and Clinical Immunology |
Volume | 139 |
Issue number | 3 |
DOIs | |
State | Published - Mar 2017 |
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Journal of Allergy and Clinical Immunology, Vol. 139, No. 3, 03.2017, p. 1052-1055.
Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Minimally important differences and risk levels for the Composite Asthma Severity Index
AU - Krouse, Rebecca Z.
AU - Sorkness, Christine A.
AU - Wildfire, Jeremy J.
AU - Calatroni, Agustin
AU - Gruchalla, Rebecca
AU - Hershey, Gurjit K.Khurana
AU - Kattan, Meyer
AU - Liu, Andrew H.
AU - Makhija, Melanie
AU - Teach, Stephen J.
AU - West, Joseph B.
AU - Wood, Robert A.
AU - Zoratti, Edward M.
AU - Gergen, Peter J.
N1 - Funding Information: This project has been funded in whole or in part with federal funds from the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Department of Health and Human Services (contract nos. HHSN272200900052C, HHSN272201000052I, and 1UM1AI114271-01). Additional support was provided by the National Center for Research Resources, and National Center for Advancing Translational Sciences, NIH (grant nos. NCRR/NIH UL1TR000451, UL1RR025780, UL1TR000075, UL1TR000154, UL1TR001082, UL1TR000077-04, UL1TR000040, UL1TR000150, and UL1TR001105). Glaxo SmithKline (GSK) provided Ventolin, Flovent, Advair, and Flonase under a clinical trial agreement with NIH-NIAID; GSK did not have a role in the development or approval of the protocol, conduct of the trial, data analysis, manuscript preparation, or the decision to submit the manuscript for publication.
PY - 2017/3
Y1 - 2017/3
UR - http://www.scopus.com/inward/record.url?scp=85006726016&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85006726016&partnerID=8YFLogxK
U2 - 10.1016/j.jaci.2016.08.041
DO - 10.1016/j.jaci.2016.08.041
M3 - Article
C2 - 27744028
AN - SCOPUS:85006726016
SN - 0091-6749
VL - 139
SP - 1052
EP - 1055
JO - Journal of Allergy and Clinical Immunology
JF - Journal of Allergy and Clinical Immunology
IS - 3
ER -